Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to Veer Biotechnology's first quarter 2026 financial results and corporate update conference call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. I will now turn the call over to Kiki Patel, Head of Investor Relations. You may begin, Kiki. Thank you, Operator, and welcome, everyone. Earlier today, we issued a press release reporting our first quarter 2026 financial results and corporate update. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration outcomes, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the potential benefits of our collaboration with Astellas, the therapeutic potential of VEER 5500 and our Pro X STEM platform, our development plans and timelines, financial terms and milestone payments, and our cash runway and capital allocation priorities. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including forms 10-K, 10-Q, and 8-K. Joining me on today's call from Veer Biotechnology are Dr. Marianne DeBacher, our Chief Executive Officer, and Jason O'Byrne, our Chief Financial Officer. During the first quarter of 2026, the VR bio team delivered meaningful advances across our T-cell engage...